Recent changes
- Jul 7, 2026Jul 7, 2026Invested in FORE Biotherapeutics (Series D-2, $67.4M) BusinessWire
- Jun 18, 2026Jun 18, 2026New fund: SR One Capital Management Fund III (target $600M) SEC EDGAR Form D
Funds
1| Fund | Vintage | Size | Strategy | Source |
|---|---|---|---|---|
| SR One Capital Management Fund III | 2026 | target $600M | Other | As of Jun 18, 2026SEC EDGAR Form D |
Portfolio
2 totalRecent Investment Activity
1| Date | Company | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|
| Jul 7, 2026 | FORE Biotherapeutics | Series D-2 | $67.4M | — | outlined = lead | Pulse story |
Co-Investors
6SR One Capital Management FAQ
What companies has SR One Capital Management invested in?
SR One Capital Management's portfolio includes ADARx, FORE Biotherapeutics.
Who does SR One Capital Management co-invest with most?
In the rounds Value Add tracks, SR One Capital Management most often invests alongside AbbVie (1 shared deal), Bain Capital Life Sciences (1 shared deal), BlackRock (1 shared deal), OrbiMed Advisors (1 shared deal), TCG Crossover (1 shared deal).
Sources & methodologyshow
Where these figures come from
- BusinessWireprimary source1 fact
- SEC EDGAR Form Dprimary source1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.